Free Trial

Heron Therapeutics (HRTX) Earnings Date, Estimates & Call Transcripts

Heron Therapeutics logo
$1.19 -0.05 (-4.03%)
(As of 11/15/2024 ET)

Heron Therapeutics Latest Earnings Summary

Upcoming Q4
Earnings Date
Mar. 11Estimated
Actual EPS
(Nov. 12)
-$0.03
Consensus EPS
(Nov. 12)
-$0.03

Heron Therapeutics issued Q3 2024 earnings on November 12, 2024, reporting an EPS of -$0.03, which met analysts' consensus estimates of -$0.03. Quarterly revenue was reported to be $32.81 million, below analyst estimates of $36.40 million. With a trailing EPS of -$0.18, Heron Therapeutics' earnings are expected to grow next year, from ($0.08) to ($0.01) per share.

HRTX Upcoming Earnings

Heron Therapeutics' next earnings date is estimated for Tuesday, March 11, 2025, based off prior year's reporting schedules.

Get Heron Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Heron Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

HRTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

HRTX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Heron Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241-$0.09-$0.09-$0.09
Q2 20242-$0.05-$0.04-$0.05
Q3 20242-$0.04-$0.03-$0.04
Q4 20242-$0.03-$0.02-$0.03
FY 20247($0.21)($0.18)($0.20)

Heron Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
3/11/2025
(Estimated)
------- 
11/12/2024Q3 2024-$0.03-$0.03--$0.03$36.40M$32.81M        
8/6/2024Q2 2024-$0.04-$0.06 -$0.02-$0.06$35.35M$36.02M        
5/7/2024Q1 2024-$0.08-$0.02+$0.06-$0.02$32.50M$34.67M    
3/12/2024Q4 2023-$0.15-$0.07+$0.08-$0.07$30.98M$34.23M    
11/14/2023Q3 2023-$0.31-$0.17+$0.14-$0.17$31.63M$31.43M    
8/14/2023Q2 2023-$0.23-$0.35 -$0.12-$0.35$31.75M$31.76M        
5/11/2023Q1 2023-$0.17-$0.27 -$0.10-$0.27$28.30M$29.62M  
3/23/2023Q4 2022-$0.25-$0.17+$0.08-$0.17$27.24M$30.00M        

Heron Therapeutics Earnings - Frequently Asked Questions

Heron Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 11th, 2025 based off last year's report dates. Learn more on HRTX's earnings history.

Heron Therapeutics issued an update on its FY 2024 earnings guidance on Tuesday, November, 12th. The company issued revenue guidance of $140.0 million-$146.0 million, compared to the consensus revenue estimate of $148.4 million.

In the previous quarter, Heron Therapeutics (NASDAQ:HRTX) reported ($0.03) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.03). Learn more on analysts' earnings estimate vs. HRTX's actual earnings.

The conference call for Heron Therapeutics's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Heron Therapeutics's latest earnings report can be read online.
Read Transcript

Heron Therapeutics (NASDAQ:HRTX) has a recorded annual revenue of $137.74 million.

Heron Therapeutics (NASDAQ:HRTX) has a recorded net income of -$110.56 million. HRTX has generated -$0.18 earnings per share over the last four quarters.

Heron Therapeutics's earnings are expected to grow from ($0.08) per share to ($0.01) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:HRTX) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners